Electra Therapeutics closed a $183 million Series C to advance its lead program, ELA026, into a pivotal trial for secondary hemophagocytic lymphohistiocytosis (HLH) and to progress other pipeline candidates. The round was co‑led by Nextech and EQT Life Sciences and included strategic investors such as Sanofi, signalling strong industry buy‑in. Electra’s antibody depletes SIRP‑expressing myeloid and T cells and aims to treat life‑threatening inflammatory syndromes and select blood cancers. Management said proceeds will fund a Phase 2/3 program for ELA026 plus additional development and manufacturing support. Sanofi’s participation reflects continued Big Pharma interest in platform immunomodulators. The financing represents active venture and strategic capital deployment into immunology and rare inflammation indications, where rapid clinical validation can unlock substantial partnership and commercial value.